Molecular brain signatures of oral contraceptives and implications for risk for depressive episodes

Vibe Frokjaer

DOI: https://doi.org/10.1016/j.psyneuen.2023.106732

IF: 4.693

2024-02-01

Psychoneuroendocrinology

Abstract:Background Strikingly, depressive episodes are twice as frequent in women as in men across the reproductive age. Some women appear to be at higher risk for developing depressive episodes when starting a hormonal contraceptive. Such “hormone sensitivity” may translate to other hormonal transitions, i.e. as shown for postpartum depression risk. Therefore, mapping plausible risk and resilience mechanism related to oral contraceptive use and depressive disorders can facilitate much needed precision psychiatry approaches to prevention and treatment of Major Depressive Disorder. Methods We here compared healthy women using combined oral contraceptives with healthy women who are natural cycling from an existing database of deep phenotyping i.e, (a) cortisol dynamics in terms of the cortisol awakening response (CAR; n=78) and, (b) a plausible molecular. markers of serotonin brain signaling critical for depression risk, development and treatment in terms of the serotonin 4 receptor (n=53). Results We demonstrated that OC-users had a blunted CAR (p=0.006) corresponding to a 61% reduction relative to non-users. Also we demonstrated that OC users have 9–12% lower global brain 5-serotonin 4 receptor brain binding potential compared to non-users (p=0.004). Conclusion Our data highlight that healthy women who use oral contraceptives differ markedly from non-users in terms of serotonin related brain architecture. Likewise, cortisol dynamics, critical for stress coping capacities, are blunted in OC users. I argue that mapping the molecular brain signatures of using oral contraceptives and other plausible critical mechanisms in the context of Major Depressive Disorder can guide clinical translations to promote brain health.

neurosciences,endocrinology & metabolism,psychiatry